行情

SGMO

SGMO

SANGAMO THERAPEU
NASDAQ

实时行情|Nasdaq Last Sale

10.42
+0.16
+1.56%
交易中 12:55 07/14 EDT
开盘
10.23
昨收
10.26
最高
10.49
最低
10.16
成交量
65.16万
成交额
--
52周最高
12.49
52周最低
4.810
市值
14.68亿
市盈率(TTM)
-12.5361
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测SGMO价格均价为20.43,最高价位36.00,最低价为11.00。

EPS

SGMO 新闻

更多
How Many Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Do Institutions Own?
Simply Wall St. · 5天前
3 Top Biotech Stocks to Watch in July
These three stocks are positioned for growth -- but investors must tread carefully in the short term.
Motley Fool · 5天前
Sangamo Announces R&D Organization Changes
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) today announced changes to its research and development organization. Going forward, research and development will each be managed as separate functions. A search for a Head of
Benzinga · 06/24 12:11
Sangamo Announces R&D Organization Changes
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization.
Business Wire · 06/24 12:00
HC Wainwright & Co. Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $14
HC Wainwright & Co. maintains Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and lowers the price target from $16 to $14.
Benzinga · 06/22 10:51
Hedge Funds Are Getting Crazy About Sangamo Therapeutics, Inc. (SGMO)
Insider Monkey · 06/19 17:22
Pfizer's hemophilia gene therapy shows sustained effect in early-stage study
Reuters · 06/18 14:44
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
Business Wire · 06/18 14:00

所属板块

生物技术和医学研究
+0.84%
制药与医学研究
+0.59%

热门股票

代码
价格
涨跌幅

SGMO 简况

Sangamo Therapeutics, Inc.(原名:Sangamo BioSciences, Inc.)专注于将科学转化为使用该公司在基因组编辑、基因治疗、基因调控和细胞治疗方面的平台技术改变患者生命的基因疗法。该公司开发了用于基因治疗的技术。其产品包括SB-525、SB-FIX、SB-318、SB-913、SB-728-T和SB-728-HSPC。其用于新型基因组编辑法的锌指核酸酶(ZFN)正于I/II期临床试验中进行评估,用于治疗血友病B和溶酶体储存障碍粘多糖贮积症(MPS)I和MPS II。它还正在进行I/II期临床试验,评估用于治疗血友病A的腺相关病毒(AAV)互补脱氧核糖核酸(cDNA)人类因子8基因疗法,SB-525。目前已有SB-525的新药申请。它还正在开发ZFN介导的基于编辑血液疾病和癌症治疗药物。
展开

微牛提供Sangamo Therapeutics Inc(NASDAQ-SGMO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的SGMO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易SGMO股票基本功能。